Cemag Invest

Diabeloop is a medical device company based in Grenoble, France, specializing in innovative solutions for diabetes management. Founded in 2015, the company focuses on developing a closed-loop system that automates insulin delivery for individuals with type 1 diabetes. Its AI-based blood sugar monitoring device integrates a sensor that continuously measures glucose levels, a pump that administers insulin, and a smartphone application that connects these components through an embedded algorithm. This technology aims to enhance the treatment experience by reducing the mental burden on patients, allowing them to manage their condition more effortlessly and live their lives with greater freedom.

Oso is a business that focuses on ambient intelligence for careers and persons in vulnerable situations. Oso is healthcare and well-being from human noises.

Avicenna.ai is a medical device company that specializes in developing advanced algorithms for the detection of life-threatening lesions, particularly in the realm of radiology. The company focuses on creating software that leverages artificial intelligence and deep learning techniques to identify acute neurovascular emergencies, such as intracranial hemorrhages and large vessel occlusions. By utilizing automatic algorithms to assess conditions like brain hemorrhages and estimate ASPECT scores, Avicenna.ai aims to enhance the diagnostic capabilities of healthcare professionals and improve patient outcomes.

Wandercraft is a robotics company that develops self-balancing robotic exoskeletons to enable paralyzed users to stand and walk hands-free, without crutches. Its flagship exoskeleton, Atalante, is a commercial device designed for daily life and rehabilitation, CE-marked in 2019 and marketed to European rehab hospitals to support gait re-learning. The company combines algorithmics, AI, robotics, production, clinical, marketing and sales to deliver a full-stack solution and aims to bring a realistic, autonomous walking device beyond lab prototypes. The exoskeleton uses motors at each joint controlled by a computing unit running software that computes robotic algorithms every millisecond to replicate a human gait, enabling paraplegic individuals to regain autonomy during daily activities.

Aryballe Technologies, established in 2014 and based in Grenoble, France, specializes in developing innovative sensors and software that mimic the human sense of smell. The company's core products include eNose, O-Cell, NeOse Pro, and Solgel, which use biochemistry, optics, and machine learning to identify, measure, and represent odors. Aryballe's solutions are designed to enhance decision-making in various industries such as food and beverage, cosmetics, and automotive, by aiding in research and development, quality control, manufacturing, and end-user experiences.

Avicenna.ai is a medical device company that specializes in developing advanced algorithms for the detection of life-threatening lesions, particularly in the realm of radiology. The company focuses on creating software that leverages artificial intelligence and deep learning techniques to identify acute neurovascular emergencies, such as intracranial hemorrhages and large vessel occlusions. By utilizing automatic algorithms to assess conditions like brain hemorrhages and estimate ASPECT scores, Avicenna.ai aims to enhance the diagnostic capabilities of healthcare professionals and improve patient outcomes.

Diabeloop is a medical device company based in Grenoble, France, specializing in innovative solutions for diabetes management. Founded in 2015, the company focuses on developing a closed-loop system that automates insulin delivery for individuals with type 1 diabetes. Its AI-based blood sugar monitoring device integrates a sensor that continuously measures glucose levels, a pump that administers insulin, and a smartphone application that connects these components through an embedded algorithm. This technology aims to enhance the treatment experience by reducing the mental burden on patients, allowing them to manage their condition more effortlessly and live their lives with greater freedom.

Cosmo Tech is a global technology company founded in 2010 by Michel Morvan and Hugues de Bantel, based in Lyon, France. Originally known as The CoSMo Company, it specializes in modeling and simulating complex systems across various industries. The company's innovative software transforms raw data into organized knowledge, enabling clients to gain clear insights and run simulations on multiple scenarios to evaluate decision outcomes. This capability supports C-suite executives in making optimal business decisions in complex environments. Over the years, Cosmo Tech has garnered industry recognition, including accolades from Gartner and EY, and has expanded its operations to North America, establishing a presence in San Francisco. With a diverse team of over 70 employees, the company continues to serve clients in both Europe and North America.

Wandercraft is a robotics company that develops self-balancing robotic exoskeletons to enable paralyzed users to stand and walk hands-free, without crutches. Its flagship exoskeleton, Atalante, is a commercial device designed for daily life and rehabilitation, CE-marked in 2019 and marketed to European rehab hospitals to support gait re-learning. The company combines algorithmics, AI, robotics, production, clinical, marketing and sales to deliver a full-stack solution and aims to bring a realistic, autonomous walking device beyond lab prototypes. The exoskeleton uses motors at each joint controlled by a computing unit running software that computes robotic algorithms every millisecond to replicate a human gait, enabling paraplegic individuals to regain autonomy during daily activities.

Advicenne is a late-stage biopharmaceutical company established in 2007 and headquartered in Nîmes, France. It focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly for orphan renal diseases and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood.